Evidence map›Paper›PMID 35778421›Full record

ArticleNPJ genomic medicine2022

PKD2 founder mutation is the most common mutation of polycystic kidney disease in Taiwan.

Chih-Chuan Yu, An-Fu Lee, Stefen Kohl, Ming-Yen Lin, Siao Muk Cheng, Chi-Chih Hung, Jer-Ming Chang, Yi-Wen Chiu, Shang-Jyh Hwang, Edgar A Otto and 3 more

Open access · goldAbstract read
In one paragraph

Article in NPJ genomic medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Kidney international reports · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. medRxiv : the preprint server for health sciences · 2024
    Article
  11. Article
  12. Long-Read Sequencing Identified aHuman mutation · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Chih-Chuan Yu *National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
An-Fu Lee *National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
Stefen KohlDepartment of Pediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Ming-Yen LinDivision of Nephrology, Department of Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Siao Muk ChengNational Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
Chi-Chih HungDivision of Nephrology, Department of Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Jer-Ming ChangDivision of Nephrology, Department of Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Yi-Wen ChiuDivision of Nephrology, Department of Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Shang-Jyh HwangDivision of Nephrology, Department of Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Edgar A OttoMichigan Medicine, Ann Arbor, MI, USA.
Friedhelm HildebrandtDepartment of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Taiwan PKD Consortium
Daw-Yang HwangNational Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan. dawyanghwang@nhri.edu.tw.ORCID http://orcid.org/0000-0002-5139-3612
Kaohsiung Medical University · TWNational Health Research Institutes · TWBoston Children's Hospital · USMichigan Medicine · USUniversity of Cologne · DE

Funding

Novel genetics, pathobiology & therapy of nephronophthisis-related ciliopathiesR01DK068306 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HILDEBRANDT, FRIEDHELM · 2004 to 2022
$6.6M
Ministry of Science and Technology, Taiwan (Ministry of Science and Technology of Taiwan) 104-2314-B-037-066Ministry of Science and Technology, Taiwan (Ministry of Science and Technology of Taiwan) 107-2314-B-400-041Ministry of Science and Technology, Taiwan (Ministry of Science and Technology of Taiwan) 108-2314-B-400-041-MY3National Health Research Institutes (NHRI) CA-110-PP-08NIDDK NIH HHS R01 DK068306
6 · The paper itself

Abstract

Autosomal Dominant polycystic kidney disease (ADPKD) is the most common inherited adult kidney disease. Although ADPKD is primarily caused by PKD1 and PKD2, the identification of several novel causative genes in recent years has revealed more complex genetic heterogeneity than previously thought. To study the disease-causing mutations of ADPKD, a total of 920 families were collected and their diagnoses were established via clinical and image studies by Taiwan PKD Consortium investigators. Amplicon-based library preparation with next-generation sequencing, variant calling, and bioinformatic analysis was used to identify disease-causing mutations in the cohort. Microsatellite analysis along with genotyping and haplotype analysis was performed in the PKD2 p.Arg803* family members. The age of mutation was calculated to estimate the time at which the mutation occurred or the founder arrived in Taiwan. Disease-causing mutations were identified in 634 families (68.9%) by detection of 364 PKD1, 239 PKD2, 18 PKHD1, 7 GANAB, and 6 ALG8 pathogenic variants. 162 families (17.6%) had likely causative but non-diagnostic variants of unknown significance (VUS). A single PKD2 p.Arg803* mutation was found in 17.8% (164/920) of the cohort in Taiwan. Microsatellite and array analysis showed that 80% of the PKD2 p.Arg803* families shared the same haplotype in a 250 kb region, indicating those families may originate from a common ancestor 300 years ago. Our findings provide a mutation landscape as well as evidence that a founder effect exists and has contributed to a major percentage of the ADPKD population in Taiwan.

Identifiers

PMID35778421
PMCPMC9249874
OpenAlexW4283765677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.